Martin Baccardax

Baccardax, a former bond salesman who spent 8 years on the trading floor in Toronto and London, has worked in and around the global financial markets for more than 25 years, covering companies from birth in the bond markets to death in the bankruptcy courts -- and all points in between.
Following television stints with CNBC Europe in London, where he served as on-air Economics editor co-anchor of the Closing Bell program, Baccardax was named London Bureau Chief in October 2016.

Recent Articles By The Author

US Crude Tops $62, Taking 2019 Gas Prices 20% Higher, Amid Iran Sanctions Talk

US Crude Tops $62, Taking 2019 Gas Prices 20% Higher, Amid Iran Sanctions Talk

Global oil prices extended gain again Tuesday, taking U.S. crude past the $62 mark for the first time in nearly five months, following stronger-than-expected factory output data from the U.S. and China and reports that Washington may revoke waivers for the purchase of Iranian exports.

EU Warns Britain That No Deal Risk 'More Likely' as Brexit Crisis Deepens

EU Warns Britain That No Deal Risk 'More Likely' as Brexit Crisis Deepens

The U.K.'s Brexit crisis deepened Tuesday as the European Union's chief negotiator warned Britain faces crashing out of the bloc in ten day's time unless lawmakers can find a way out of the current impasse.

Lyft Makes U-Turn as Shares Skid on 2nd Day of Trading

Lyft Makes U-Turn as Shares Skid on 2nd Day of Trading

Lyft shares slumped below their original listing price on the second full-day of trading on the Nasdaq Monday following the ride-sharing group's blockbuster IPO last week, the biggest in five years, that raised $2.34 billion and dominated Wall Street trading.

Oil Extends Gains From Best Quarter Since 2009 as China Factory Output Rumbles

Oil Extends Gains From Best Quarter Since 2009 as China Factory Output Rumbles

Global oil prices traded firmly higher Monday, extending gains from the strongest quarter in a decade, after stronger-than-expected factory output data from China and ongoing production cuts from OPEC member and its allies raised the prospect of increasing demand into the summer months.

Apple Shares Slide on Report of iPhone Price Cuts in China

Apple Shares Slide on Report of iPhone Price Cuts in China

Apple shares traded sharply lower Monday, reversing earlier gains, following a report that suggested the tech giant has slashed sale prices for its iPhone and Mac products in China.

Merck Shares Gain After Lung Cancer Drug Keytruda Approved for Sale In China

Merck Shares Gain After Lung Cancer Drug Keytruda Approved for Sale In China

Merck shares edged higher Monday after the drugmaker won approval for the sale of its blockbuster lung cancer treatment in China.

Facebook Edges Higher as Zuckerberg Frontruns Regulatory Pressure with Post OpEd

Facebook Edges Higher as Zuckerberg Frontruns Regulatory Pressure with Post OpEd

Facebook shares traded higher Monday following a weekend editorial from founder and CEO Mark Zuckerberg that called for a larger government rule in policing the internet amid reports the social media group faces a multi-billion dollar fine over its privacy failures.

Trump Calls for Fed Rate Cuts, Markets Unmoved Ahead of Key Friday Jobs Report

Trump Calls for Fed Rate Cuts, Markets Unmoved Ahead of Key Friday Jobs Report

U.S. equities capped their strongest three month gain in a decade over the first quarter, while the economy continues to expand and the jobless rate sits at the lowest level in a generation, but President Donald Trump and his team think the Federal Reserve should move quickly to cut interest rates in order to ensure the current boom remains on track.

Global Stocks Gain on China Manufacturing Recovery, Trade Talk Progress

Global Stocks Gain on China Manufacturing Recovery, Trade Talk Progress

Global stocks rebounded firmly Monday, boosted by the strongest reading of manufacturing output in China in at least eight months and further suggestions of trade talk progress between Washington and Beijing, although gains were capped by weaker factory output readings across Europe in Japan.

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Celgene surges Friday after an influential shareholder advisory group recommend investors vote in favor of the cancer drug specialist's takeover by Bristol-Myers Squibb Co. while a key activist dropped its opposition to the $74 billion deal.